Chiasma Inc (NASDAQ:CHMA) Expected to Post Earnings of -$0.22 Per Share
Equities research analysts forecast that Chiasma Inc (NASDAQ:CHMA) will announce earnings per share of ($0.22) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Chiasma’s earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.28). Chiasma posted earnings of ($0.32) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 31.3%. The business is scheduled to announce its next earnings report on Friday, March 13th.
On average, analysts expect that Chiasma will report full year earnings of ($1.03) per share for the current financial year, with EPS estimates ranging from ($1.08) to ($0.92). For the next year, analysts expect that the business will post earnings of ($1.11) per share, with EPS estimates ranging from ($1.72) to ($0.67). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow Chiasma.
Chiasma (NASDAQ:CHMA) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.01.
Shares of NASDAQ:CHMA traded up $0.08 during trading on Friday, reaching $5.10. 118,400 shares of the company traded hands, compared to its average volume of 367,530. The company’s 50 day moving average is $5.08 and its two-hundred day moving average is $5.93. The firm has a market capitalization of $211.34 million, a PE ratio of -3.98 and a beta of 1.19. Chiasma has a 52 week low of $2.11 and a 52 week high of $9.25.
In other news, Director Scott Minick bought 9,818 shares of the stock in a transaction on Tuesday, August 20th. The stock was acquired at an average price of $5.19 per share, with a total value of $50,955.42. Following the acquisition, the director now directly owns 62,531 shares in the company, valued at $324,535.89. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Roni Mamluk sold 10,000 shares of the company’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $4.94, for a total value of $49,400.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $49,400. The disclosure for this sale can be found here. In the last ninety days, insiders acquired 17,268 shares of company stock valued at $96,823. Insiders own 8.30% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of CHMA. Vivo Capital LLC acquired a new position in Chiasma in the 2nd quarter worth about $17,758,000. BlackRock Inc. increased its stake in shares of Chiasma by 868.1% in the second quarter. BlackRock Inc. now owns 1,601,272 shares of the biotechnology company’s stock valued at $11,962,000 after buying an additional 1,435,873 shares during the period. Vanguard Group Inc. increased its stake in shares of Chiasma by 30.9% in the second quarter. Vanguard Group Inc. now owns 1,051,908 shares of the biotechnology company’s stock valued at $7,858,000 after buying an additional 248,574 shares during the period. Renaissance Technologies LLC increased its stake in shares of Chiasma by 85.2% in the second quarter. Renaissance Technologies LLC now owns 411,883 shares of the biotechnology company’s stock valued at $3,077,000 after buying an additional 189,500 shares during the period. Finally, Fosun International Ltd acquired a new stake in shares of Chiasma in the second quarter valued at about $923,000. 53.90% of the stock is owned by institutional investors and hedge funds.
Chiasma Company Profile
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
Featured Story: What is the Quick Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.